文献速递白血病造血干细胞移植与细胞治疗

活动性复发难治急性髓系白血病挽救性异基因移植510例真实世界研究

[Allogeneic hematopoietic stem cell transplantation for 510 patients with active relapsed/refractory acute myeloid leukemia: a real-world study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该回顾性真实世界研究纳入510例移植前骨髓原始细胞≥5%的活动性复发难治急性髓系白血病患者,接受挽救性异基因造血干细胞移植,中位随访50个月,预估10年总生存率和无病生存率分别为35.5%和33.2%。多因素分析显示ELN风险分层是核心预后因素,轻度至中度慢性GVHD为保护因素,移植前肿瘤负荷主要影响复发风险但非长期生存独立决定因素。

要点

  • 活动性R/R AML患者接受挽救性allo-HSCT仍可能获得长期无病生存,10年OS率35.5%、DFS率33.2%。
  • ELN中危和高危是OS、DFS降低及复发风险升高的独立因素,应重视移植前风险分层。
  • 轻度至中度cGVHD与更好OS、DFS及更低复发相关,但重度cGVHD增加非复发死亡。

核心结论

  • 移植前仍处活动性的R/R AML患者接受挽救性allo-HSCT仍可能获得长期无病生存。
  • 长期结局主要由疾病生物学特征和移植后免疫效应决定,ELN风险分层与GVHD起主导作用。
  • 移植前肿瘤负荷主要影响复发风险,但并非长期生存的独立决定因素。

研究设计与样本

  • 回顾性真实世界研究,纳入2012年7月至2024年12月于航天中心医院接受allo-HSCT的510例R/R AML患者。
  • 所有患者移植前骨髓原始细胞比例均≥5%,属活动性疾病。
  • 采用Kaplan-Meier法评估OS和DFS,竞争风险模型分析CIR和NRM,多因素采用Cox回归和Fine-Gray模型。

主要发现

  • 中位随访50个月(范围0~151个月),预估10年OS率为35.5%(95%CI:31.2%~40.5%),DFS率为33.2%(95%CI:29.1%~38.0%)。
  • 与低危组相比,ELN中危和高危患者OS和DFS均显著降低(OS:HR=1.74、1.97,P=0.002、<0.001;DFS:HR=1.77、1.99,均P<0.001)。
  • 发病至移植时间≤10个月与更好的OS和DFS独立相关(OS:HR=0.64,P<0.001;DFS:HR=0.62,P<0.001)。
  • CD34(+)细胞输注量不足(≤4.3×10(6)/kg)是OS和DFS的不良预后因素(OS:HR=1.57,P<0.001;DFS:HR=1.62,P<0.001)。
  • 竞争风险分析中,ELN高危(HR=2.90,P<0.001)、移植前骨髓原始细胞≥50%(HR=1.62,P=0.037)及CD34(+)细胞输注量不足(HR=1.64,P=0.003)与较高CIR独立相关。

关键数值与推荐

  • Ⅲ~Ⅳ级aGVHD与较低CIR相关(HR=0.54,P=0.033)。
  • 轻、中、重度cGVHD均与较低CIR相关(HR分别为0.38、0.13、0.24,P分别为<0.001、<0.001、0.015)。
  • Ⅲ~Ⅳ级aGVHD是非复发死亡主要危险因素(HR=2.36,P<0.001)。
  • 年龄≤35岁患者非复发死亡风险较低(HR=0.68,P=0.033)。

临床怎么用

  • 临床应重视移植前ELN风险分层及移植时机选择,而非单纯追求移植前完全缓解。
  • 可关注CD34(+)细胞输注量(≥4.3×10(6)/kg)对长期生存的潜在影响。
  • 移植后轻度至中度cGVHD与较好生存相关,但需警惕Ⅲ~Ⅳ级aGVHD增加非复发死亡。

局限性

  • 本研究为单中心回顾性真实世界研究,结果解读需考虑选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the long-term survival outcomes of salvage allogeneic hematopoietic stem cell transplantation (R/R AML) . Methods: This was a retrospective real-world study. We conducted a retrospective analysis of 510 patients with R/R AML who underwent allo-HSCT at Aerospace Center Hospital between July 2012 and December 2024. All patients had active disease before transplantation, defined as a bone marrow blast proportion of at least 5%. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method, whereas the cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were evaluated by competing-risk models. Univariate analysis was performed using the log-rank test, and multivariable analysis was conducted using Cox regression for survival outcomes and Fine-Gray regression for competing-risk outcomes to identify independent prognostic factors. Results: In this cohort of 510 patients, the median follow-up duration was 50 months (range, 0-151 months). The estimated 10-year overall survival (OS) and disease-free survival (DFS) rates were 35.5% (95% CI: 31.2% -40.5% ) and 33.2% (95% CI: 29.1% -38.0% ), respectively. Multivariable analysis demonstrated that European LeukemiaNet (ELN) risk stratification was a core prognostic factor. Patients in the intermediate-risk (HR=1.74, P=0.002) and adverse-risk (HR=1.97, P<0.001) categories had markedly lower OS and DFS rates. Mild-to-moderate chronic graft-versus-host disease (cGVHD) served as a protective factor for OS and DFS (both P<0.001). A diagnosis-to-transplant interval longer than 10 months (HR=1.56, P<0.001) was correlated with poor survival outcomes. A higher infused CD34(+) cell dose (≥4.3×10(6)/kg) was independently associated with superior OS (HR=0.64, P<0.001) and DFS (HR=0.62, P<0.001). In competing-risk analysis, intermediate and adverse ELN risk stratification (HR=2.73 and 2.90, respectively; both P<0.001) and elevated bone marrow blast percentage (≥50% ) (HR=1.62, P=0.037) were independently linked to increased relapse risk. Mild, moderate, and severe cGVHD, compared with no cGVHD (HR=0.38, 0.13, and 0.24; P<0.001, P<0.001, and P=0.015, respectively), and grade Ⅲ-Ⅳ acute graft-versus-host disease (aGVHD) (HR=0.54, P=0.033) were associated with a lower CIR. Regarding non-relapse mortality (NRM), grade Ⅲ-Ⅳ aGVHD (HR=2.36, P<0.001) and severe cGVHD (HR=2.74, P<0.001) were major risk factors, and advanced age (HR=1.47, P=0.033) was also associated with higher NRM. Conclusions: This study indicates that long-term disease-free survival may be attained through salvage allo-HSCT in patients with R/R AML despite active disease at transplantation. Long-term outcomes are mainly determined by disease biology and post-transplant immune effects, with ELN risk stratification and GVHD playing dominant roles, whereas pre-transplant tumor burden mainly affects relapse risk but is not an independent determinant of long-term survival. These findings suggest that greater emphasis should be placed on risk stratification and transplantation timing in clinical practice, rather than solely pursuing complete remission prior to transplantation. 目的: 探讨活动性复发难治性急性髓系白血病(R/R AML)患者接受挽救性异基因造血干细胞移植(allo-HSCT)的长期生存结局及其影响因素。 方法: 本研究为回顾性真实世界研究。选取2012年7月至2024年12月于航天中心医院接受allo-HSCT的510例R/R AML患者,所有患者移植前骨髓原始细胞比例均≥5%。采用Kaplan-Meier法评估总生存(OS)和无病生存(DFS),采用竞争风险模型分析累积复发率(CIR)及非复发死亡率(NRM)。通过单因素Log-rank检验及多因素Cox回归模型和Fine-Gray模型筛选影响预后的独立危险因素。 结果: 中位随访时间为50(0~151)个月,510例患者预估10年OS率和DFS率分别为35.5%(95%CI:31.2%~40.5%)和33.2%(95%CI:29.1%~38.0%)。多因素分析显示,ELN风险分层是影响预后的核心因素,与低危组相比,中危及高危患者OS和DFS均显著降低(OS:HR=1.74、1.97,P=0.002、<0.001;DFS:HR=1.77、1.99,均P<0.001)。发病至移植时间≤10个月与更好的OS和DFS独立相关(OS:HR=0.64,P<0.001;DFS:HR=0.62,P<0.001),而CD34(+)细胞输注量不足(≤4.3×10(6)/kg)是OS和DFS的不良预后因素(OS:HR=1.57,P<0.001;DFS:HR=1.62,P<0.001)。在竞争风险分析中,ELN高危分层(HR=2.90,P<0.001)、移植前骨髓原始细胞比例≥50%(HR=1.62,P=0.037)以及CD34(+)细胞输注量不足(HR=1.64,P=0.003)与较高的累积复发率(CIR)独立相关;Ⅲ~Ⅳ级急性GVHD(HR=0.54,P=0.033)及轻、中、重度cGVHD(HR分别为0.38、0.13、0.24,P分别为<0.001、<0.001、0.015)均与较低CIR相关。对于非复发死亡,Ⅲ~Ⅳ级aGVHD(HR=2.36,P<0.001)是主要危险因素,年龄≤35岁患者非复发死亡风险较低(HR=0.68,P=0.033)。 结论: 对于移植前仍存在活动性的R/R AML患者,直接行挽救性allo-HSCT仍可能获得长期无病生存。长期预后主要由疾病生物学特征及移植后免疫效应共同决定,其中ELN风险分层和GVHD在结局中起主导作用,而移植前肿瘤负荷主要影响复发风险但并非长期生存的独立决定因素。因此在临床实践中应更加重视风险分层及移植时机选择,而非单纯追求移植前完全缓解。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Man XY, Li ML, Fei XH, et al. [Allogeneic hematopoietic stem cell transplantation for 510 patients with active relapsed/refractory acute myeloid leukemia: a real-world study]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706153. doi:10.3760/cma.j.cn121090-20260120-00040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。